Phenotypes of Chronic Obstructive Pulmonary Disease

REFERENCES

• Pauwels R. Global initiative for chronic obstructive lung diseases (gold): Time to act. Eur Respir J 2001; 18: 901–902
   PubMed Web of Science ®Google Scholar
• Pauwels R A, Buist A S, Calverley P M, Jenkins C R, Hurd S S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Nhlbi/who global initiative for chronic obstructive lung disease (gold) workshop summary. Amer J Respir Crit Care Med 2001; 163: 1256–1276
   PubMedGoogle Scholar
• American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American thoracic society. Amer J Respir Criti Care Med 1995; 152: S77–121
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Wright E C, Hodgkin J E. Prognosis in chronic obstructive pulmonary disease. Amer Rev Respir Dis 1986; 133: 14–20
   PubMed Web of Science ®Google Scholar
• Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal oxygen therapy trial group. Ann Intern Med 1980; 93: 391–398
   PubMed Web of Science ®Google Scholar
• Dolan S, Varkey B. Prognostic factors in chronic obstructive pulmonary disease. Curr Opin Pulmon Med 2005; 11: 149–152
   PubMed Web of Science ®Google Scholar
• Wolkove N, Dajczman E, Colacone A, Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989; 96: 1247–1251
   PubMed Web of Science ®Google Scholar
• Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 1998; 157: 785–790
   PubMed Web of Science ®Google Scholar
• Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T, Izumi T. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest 1999; 116: 1632–1637
   PubMed Web of Science ®Google Scholar
• Fletcher C M, Elmes P C, Fairbairn A S, Wood C H. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2: 257–266
   PubMed Web of Science ®Google Scholar
• BTS. Guidelines for the management of chronic obstructive pulmonary disease. The copd guidelines group of the standards of care committee of the BTS. Thorax 1997; 52: S1–28, Suppl 5
   PubMed Web of Science ®Google Scholar
• Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–1440
   PubMed Web of Science ®Google Scholar
• Celli B R, Cote C G, Marin J M, Casanova C, Montes de Oca M, Mendez R A, Pinto Plata V, Cabral H J. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New Engl J Med 2004; 350: 1005–1012
   PubMed Web of Science ®Google Scholar
• Fan V S, Curtis J R, Tu S P, McDonell M B, Fihn S D. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest 2002; 122: 429–436
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Farrero E, Felez M A, Izquierdo J, Marrades R M, Anto J M. Risk factors of readmission to hospital for a COPD exacerbation: A prospective study. Thorax 2003; 58: 100–105
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Monso E, Marrades R M, Escarrabill J, Felez M A, Sunyer J, Anto J M. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. Efram study. Amer J Respir Crit Care Med 2001; 164: 1002–1007
   PubMed Web of Science ®Google Scholar
• Niewoehner D E, Lokhnygina Y, Rice K, Kuschner W G, Sharafkhaneh A, Sarosi G A, Krumpe P, Pieper K, Kesten S. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007; 131: 20–28
   PubMed Web of Science ®Google Scholar
• Roberts C M, Lowe D, Bucknall C E, Ryland I, Kelly Y, Pearson M G. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002; 57: 137–141
   PubMed Web of Science ®Google Scholar
• Skrepnek G H, Skrepnek S V. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Amer J Manag Care 2004; 10: S129–138
   PubMed Web of Science ®Google Scholar
• Parshall M B. Adult emergency visits for chronic cardiorespiratory disease: Does dyspnea matter?. Nurs Res 1999; 48: 62–70
   PubMed Web of Science ®Google Scholar
• Patil S P, Krishnan J A, Lechtzin N, Diette G B. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003; 163: 1180–1186
   PubMed Web of Science ®Google Scholar
• Groenewegen K H, Schols A M, Wouters E F. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459–467
   PubMed Web of Science ®Google Scholar
• Goel A, Pinckney R G, Littenberg B. Apache ii predicts long-term survival in copd patients admitted to a general medical ward. J Gen Intern Med 2003; 18: 824–830
   PubMed Web of Science ®Google Scholar
• Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia J L, Garau J. Mortality after hospitalization for COPD. Chest 2002; 121: 1441–1448
   PubMed Web of Science ®Google Scholar
• Decramer M, Gosselink R, Bartsch P, Lofdahl C G, Vincken W, Dekhuijzen R, Vestbo J, Pauwels R, Naeije R, Troosters T. Effect of treatments on the progression of COPD: Report of a workshop held in leuven, 11–12 march 2004. Thorax 2005; 60: 343–349
   PubMedGoogle Scholar
• Mapel D W. Treatment implications on morbidity and mortality in COPD. Chest 2004; 126: 150S–158S, Discussion 159S–161S
   PubMedGoogle Scholar
• Sin D D, Wu L, Anderson J A, Anthonisen N R, Buist A S, Burge P S, Calverley P M, Connett J E, Lindmark B, Pauwels R A, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992–997
   PubMed Web of Science ®Google Scholar
• Schols A M, Slangen J, Volovics L, Wouters E F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Amer J Respir Criti Care Med 1998; 157: 1791–1797
   PubMed Web of Science ®Google Scholar
• Schols A M, Broekhuizen R, Weling-Scheepers C A, Wouters E F. Body composition and mortality in chronic obstructive pulmonary disease. Amer J Clin Nutr 2005; 82: 53–59
   PubMed Web of Science ®Google Scholar
• Prescott E, Almdal T, Mikkelsen K L, Tofteng C L, Vestbo J, Lange P. Prognostic value of weight change in chronic obstructive pulmonary disease: Results from the copenhagen city heart study. Eur Respir J 2002; 20: 539–544
   PubMed Web of Science ®Google Scholar
• Kotler D P. Cachexia. Ann Intern Med 2000; 133: 622–634
   PubMed Web of Science ®Google Scholar
• Chailleux E, Laaban J P, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: Data from the antadir observatory. Chest 2003; 123: 1460–1466
   PubMed Web of Science ®Google Scholar
• Schols A M. Nutrition in chronic obstructive pulmonary disease. Curr Opin Pulmon Med 2000; 6: 110–115
   PubMedGoogle Scholar
• Schols A M, Soeters P B, Dingemans A M, Mostert R, Frantzen P J, Wouters E F. Prevalence and characteristics of nutritional depletion in patients with stable copd eligible for pulmonary rehabilitation. Amer Rev Respir Dis 1993; 147: 1151–1156
   PubMed Web of Science ®Google Scholar
• Engelen M P, Wouters E F, Deutz N E, Does J D, Schols A M. Effects of exercise on amino acid metabolism in patients with chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 2001; 163: 859–864
   PubMed Web of Science ®Google Scholar
• Engelen M P, Schols A M, Does J D, Gosker H R, Deutz N E, Wouters E F. Exercise-induced lactate increase in relation to muscle substrates in patients with chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 2000; 162: 1697–1704
   PubMed Web of Science ®Google Scholar
• Debigare R, Cote C H, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Amer J Respir Crit Care Med 2001; 164: 1712–1717
   PubMed Web of Science ®Google Scholar
• Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard B G, Andersen T, Sorensen T I, Lange P. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: Findings from the copenhagen city heart study. Amer J Respir Crit Care Med 2006; 173: 79–83
   PubMed Web of Science ®Google Scholar
• Agusti A G, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347–360
   PubMed Web of Science ®Google Scholar
• Balasubramanian V P, Varkey B. Chronic obstructive pulmonary disease: Effects beyond the lungs. Curr Opin Pulmon Med 2006; 12: 106–112
   PubMed Web of Science ®Google Scholar
• Wouters E F, Creutzberg E C, Schols A M. Systemic effects in COPD. Chest 2002; 121: 127S–130S
   PubMed Web of Science ®Google Scholar
• Jagoe R T, Engelen M P. Muscle wasting and changes in muscle protein metabolism in chronic obstructive pulmonary disease. Eur Respir J 2003; 46: 52s–63s
   Google Scholar
• Gosker H R, Kubat B, Schaart G, van der Vusse G J, Wouters E F, Schols A M. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 280–285
   PubMed Web of Science ®Google Scholar
• Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease (copd), with and without chronic respiratory failure. Eur Respir J 1990; 3: 192–196
   PubMed Web of Science ®Google Scholar
• Hildebrand I L, Sylven C, Esbjornsson M, Hellstrom K, Jansson E. Does chronic hypoxaemia induce transformations of fibre types?. Acta Physiol Scand 1991; 141: 435–439
   PubMedGoogle Scholar
• Sato Y, Asoh T, Honda Y, Fujimatsu Y, Higuchi I, Oizumi K. Morphologic and histochemical evaluation of muscle in patients with chronic pulmonary emphysema manifesting generalized emaciation. Euro Neurol 1997; 37: 116–121
   PubMed Web of Science ®Google Scholar
• Maltais F. LeBlanc P Simard C Jobin J Berube C Bruneau J Carrier L Belleau R. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 1996; 154: 442–447
   PubMed Web of Science ®Google Scholar
• Serres I, Varray A, Vallet G, Micallef J P, Prefaut C. Improved skeletal muscle performance after individualized exercise training in patients with chronic obstructive pulmonary disease. J Cardiopul Rehab 1997; 17: 232–238
   PubMedGoogle Scholar
• Vallet G, Ahmaidi S, Serres I, Fabre C, Bourgouin D, Desplan J, Varray A, Prefaut C. Comparison of two training programmes in chronic airway limitation patients: Standardized versus individualized protocols. Eur Respir J 1997; 10: 114–122
   PubMed Web of Science ®Google Scholar
• Couillard A, Prefaut C. From muscle disuse to myopathy in copd: Potential contribution of oxidative stress. Eur Respir J 2005; 26: 703–719
   PubMed Web of Science ®Google Scholar
• Agusti A G, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, Batle S, Busquets X. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 2002; 166: 485–489
   PubMed Web of Science ®Google Scholar
• Swallow E B, Reyes D, Hopkinson N S, Man W D, Porcher R, Cetti E J, Moore A J, Moxham J, Polkey M I. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007; 62: 115–120
   PubMed Web of Science ®Google Scholar
• Li X, Moody M R, Engel D, Walker S, Clubb F J, Jr, Sivasubramanian N, Mann D L, Reid M B. Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 2000; 102: 1690–1696
   PubMed Web of Science ®Google Scholar
• Creutzberg E C, Schols A M, Weling-Scheepers C A, Buurman W A, Wouters E F. Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 2000; 161: 745–752
   PubMed Web of Science ®Google Scholar
• Agusti A, Morla M, Sauleda J, Saus C, Busquets X. Nf-kappab activation and inos upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 2004; 59: 483–487
   PubMed Web of Science ®Google Scholar
• Rabinovich R A, Bastos R, Ardite E, Llinas L, Orozco-Levi M, Gea J, Vilaro J, Barbera J A, Rodriguez-Roisin R, Fernandez-Checa J C, et al. Mitochondrial dysfunction in copd patients with low body mass index. Eur Respir J 2007; 29: 643–650
   PubMed Web of Science ®Google Scholar
• Couillard A, Koechlin C, Cristol J P, Varray A, Prefaut C. Evidence of local exercise-induced systemic oxidative stress in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20: 1123–1129
   PubMed Web of Science ®Google Scholar
• Rahman I, Skwarska E. MacNee W. Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease. Thorax 1997; 52: 565–568
   PubMed Web of Science ®Google Scholar
• Palazzetti S, Rousseau A S, Richard M J, Favier A, Margaritis I. Antioxidant supplementation preserves antioxidant response in physical training and low antioxidant intake. Br J Nutr 2004; 91: 91–100
   PubMed Web of Science ®Google Scholar
• Budweiser S, Heinemann F, Meyer K, Wild P J, Pfeifer M. Weight gain in cachectic copd patients receiving noninvasive positive-pressure ventilation. Respir Care 2006; 51: 126–132
   PubMed Web of Science ®Google Scholar
• Donohue J F. Minimal clinically important differences in copd lung function. COPD 2005; 2: 111–124
   PubMedGoogle Scholar
• Petty T L. COPD in perspective. Chest 2002; 121: 116S–120S
   PubMed Web of Science ®Google Scholar
• Paggiaro P L, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International copd study group. Lancet 1998; 351: 773–780
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999; 353: 1819–1823
   PubMed Web of Science ®Google Scholar
• Pauwels R A, Lofdahl C G, Laitinen L A, Schouten J P, Postma D S, Pride N B, Ohlsson S V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European respiratory society study on chronic obstructive pulmonary disease. New Engl J Med 1999; 340: 1948–1953
   PubMed Web of Science ®Google Scholar
• Burge P S, Calverley P M, Jones P W, Spencer S, Anderson J A, Maslen T K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The isolde trial. BMJ (Clin Res Ed) 2000; 320: 1297–1303
   PubMed Web of Science ®Google Scholar
• The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New Engl J Med 2000; 343: 1902–1909
   PubMed Web of Science ®Google Scholar
• Mahler D A, Wire P, Horstman D, Chang C N, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 2002; 166: 1084–1091
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003; 361: 449–456
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81
   PubMed Web of Science ®Google Scholar
• Hanania N A, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the diskus inhaler for the treatment of copd. Chest 2003; 124: 834–843
   PubMed Web of Science ®Google Scholar
• Sutherland E R, Allmers H, Ayas N T, Venn A J, Martin R J. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: A meta-analysis. Thorax 2003; 58: 937–941
   PubMed Web of Science ®Google Scholar
• Vestbo J, Pauwels R, Anderson J A, Jones P, Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005; 60: 301–304
   PubMed Web of Science ®Google Scholar
• Calverley P M, Anderson J A, Celli B, Ferguson G T, Jenkins C, Jones P W, Yates J C, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New Engl J Med 2007; 356: 775–789
   PubMed Web of Science ®Google Scholar
• Soriano J B, Sin D D, Zhang X, Camp P G, Anderson J A, Anthonisen N R, Buist A S, Burge P S, Calverley P M, Connett J E, et al. A pooled analysis of fev1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007; 131: 682–689
   PubMed Web of Science ®Google Scholar
• Barnes P J, Ito K, Adcock I M. Corticosteroid resistance in chronic obstructive pulmonary disease: Inactivation of histone deacetylase. Lancet 2004; 363: 731–733
   PubMed Web of Science ®Google Scholar
• Barnes P J, Shapiro S D, Pauwels R A. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur Respir J 2003; 22: 672–688
   PubMed Web of Science ®Google Scholar
• Cully J A, Graham D P, Stanley M A, Ferguson C J, Sharafkhaneh A, Souchek J, Kunik M E. Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics 2006; 47: 312–319
   PubMed Web of Science ®Google Scholar
• Dahlen I, Janson C. Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest 2002; 122: 1633–1637
   PubMed Web of Science ®Google Scholar
• Kim H F, Kunik M E, Molinari V A, Hillman S L, Lalani S, Orengo C A, Petersen N J, Nahas Z, Goodnight-White S. Functional impairment in copd patients: The impact of anxiety and depression. Psychosomatics 2000; 41: 465–471
   PubMed Web of Science ®Google Scholar
• van de E L, Yzermans C J, Brouwer H J. Prevalence of depression in patients with chronic obstructive pulmonary disease: A systematic review. Thorax 1999; 54: 688–692
   PubMed Web of Science ®Google Scholar
• Smoller J W, Simon N M, Pollack M H, Kradin R, Stern T. Anxiety in patients with pulmonary disease: Comorbidity and treatment. Semin Clin Neuropsych 1999; 4: 84–97
   PubMedGoogle Scholar
• Brenes G A. Anxiety and chronic obstructive pulmonary disease: Prevalence, impact, and treatment. Psychosom Med 2003; 65: 963–970
   PubMed Web of Science ®Google Scholar
• Prigatano G P, Wright E C, Levin D. Quality of life and its predictors in patients with mild hypoxemia and chronic obstructive pulmonary disease. Arch Intern Med 1984; 144: 1613–1619
   PubMed Web of Science ®Google Scholar
• Kvaal K, Macijauskiene J, Engedal K, Laake K. High prevalence of anxiety symptoms in hospitalized geriatric patients. Inter J Geriatr Psych 2001; 16: 690–693
   PubMed Web of Science ®Google Scholar
• Kunik M E, Roundy K, Veazey C, Souchek J, Richardson P, Wray N P, Stanley M A. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005; 127: 1205–1211
   PubMed Web of Science ®Google Scholar
• van Manen J G, Bindels P J, Dekker F W, CJ I J, van der Zee J S, Schade E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002; 57: 412–416
   PubMed Web of Science ®Google Scholar
• Di Marco F, Verga M, Reggente M. Maria Casanova F Santus P Blasi F Allegra L Centanni S. Anxiety and depression in copd patients: The roles of gender and disease severity. Respir Med 2006; 100: 1767–1774
   PubMed Web of Science ®Google Scholar
• Felker B, Katon W, Hedrick S C, Rasmussen J, McKnight K, McDonnell M B, Fihn S D. The association between depressive symptoms and health status in patients with chronic pulmonary disease. Gen Hosp Psych 2001; 23: 56–61
   PubMed Web of Science ®Google Scholar
• Neuman A, Gunnbjornsdottir M, Tunsater A, Nystrom L, Franklin K A, Norrman E, Janson C. Dyspnea in relation to symptoms of anxiety and depression: A prospective population study. Respir Med 2006; 100: 1843–1849
   PubMed Web of Science ®Google Scholar
• Agle D P, Baum G L. Psychological aspects of chronic obstructive pulmonary disease. Med Clin N Amer 1977; 61: 749–758
   PubMed Web of Science ®Google Scholar
• Norwood R, Balkissoon R. Current perspectives on management of co-morbid depression in copd. COPD 2005; 2: 185–193
   PubMedGoogle Scholar
• Borson S, Claypoole K, McDonald G J. Depression and chronic obstructive pulmonary disease: Treatment trials. Semin Clin Neuropsych 1998; 3: 115–130
   PubMedGoogle Scholar
• Wamboldt F S. Anxiety and depression in COPD: A call (and need) for further research. COPD 2005; 2: 199–201
   PubMedGoogle Scholar
• Clark D M. A cognitive approach to panic. Behav Res Ther 1986; 24: 461–470
   PubMed Web of Science ®Google Scholar
• Moore M C, Zebb B J. The catastrophic misinterpretation of physiological distress. Behav Res Ther 1999; 37: 1105–1118
   PubMed Web of Science ®Google Scholar
• Behrendt C E. Mild and moderate-to-severe copd in nonsmokers: Distinct demographic profiles. Chest 2005; 128: 1239–1244
   PubMed Web of Science ®Google Scholar
• Birring S S, Brightling C E, Bradding P, Entwisle J J, Vara D D, Grigg J, Wardlaw A J, Pavord I D. Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary disease in nonsmokers: A descriptive study. Amer J Respir Crit Care Med 2002; 166: 1078–1083
   PubMed Web of Science ®Google Scholar
• Pena V S, Miravitlles M, Gabriel R, Jimenez-Ruiz C A, Villasante C, Masa J F, Viejo J L, Fernandez-Fau L. Geographic variations in prevalence and underdiagnosis of copd: Results of the iberpoc multicentre epidemiological study. Chest 2000; 118: 981–989
   PubMed Web of Science ®Google Scholar
• Ekici A, Ekici M, Kurtipek E, Akin A, Arslan M, Kara T, Apaydin Z, Demir S. Obstructive airway diseases in women exposed to biomass smoke. Environ Res 2005; 99: 93–98
   PubMed Web of Science ®Google Scholar
• Matheson M C, Benke G, Raven J, Sim M R, Kromhout H, Vermeulen R, Johns D P, Walters E H, Abramson M J. Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease. Thorax 2005; 60: 645–651
   PubMed Web of Science ®Google Scholar
• Tashkin D P, Detels R, Simmons M, Liu H, Coulson A H, Sayre J, Rokaw S. The ucla population studies of chronic obstructive respiratory disease: Xi. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. Amer J Respir Crit Care Med 1994; 149: 1209–1217
   PubMed Web of Science ®Google Scholar
• Silva G E, Sherrill D L, Guerra S, Barbee R A. Asthma as a risk factor for copd in a longitudinal study. Chest 2004; 126: 59–65
   PubMed Web of Science ®Google Scholar
• O'Connor G T, Sparrow D, Weiss S T. A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary-function decline: The normative aging study. Amer J Respir Crit Care Med 1995; 152: 87–92
   PubMed Web of Science ®Google Scholar
• Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard B G. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin mz heterozygotes: A longitudinal study of the general population. Ann Intern Med 2002; 136: 270–279
   PubMed Web of Science ®Google Scholar
• Kraft M, Mortenson R L, Colby T V, Newman L, Waldron J A, Jr, King T E, Jr. Cryptogenic constrictive bronchiolitis. A clinicopathologic study. Amer Rev Respir Dis 1993; 148: 1093–1101
   PubMed Web of Science ®Google Scholar
• Turton C W, Firth G, Grundy E, Rigden B G, Smyth J T, Turner-Warwick M. Raised enzyme markers of chronic inflammation in asymptomatic farmers' lung. Thorax 1981; 36: 122–125
   PubMed Web of Science ®Google Scholar
• Homma H, Yamanaka A, Tanimoto S, Tamura M, Chijimatsu Y, Kira S, Izumi T. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest 1983; 83: 63–69
   PubMed Web of Science ®Google Scholar
• Aguayo S M, Miller Y E, Waldron J A, Jr, Bogin R M, Sunday M E, Staton G W, Jr, Beam W R, King T E, Jr. Brief report: Idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. New Engl J Med 1992; 327: 1285–1288
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstrcutive Lung Disease. Executive summary: Global strategy for the diagnosis, management, and prevention of chronic obstrcutive pulmonary disease. 2006, http://wwwgoldcopdcom(accessed January 2007)
   Google Scholar
• Siafakas N M, Vermeire P, Pride N B, Paoletti P, Gibson J, Howard P, Yernault J C, Decramer M, Higenbottam T, Postma D S, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398–1420
   PubMed Web of Science ®Google Scholar
• Speizer F E, Fay M E, Dockery D W, Ferris B G, Jr. Chronic obstructive pulmonary disease mortality in six U.S. Cities. Amer Rev Respir Dis 1989; 140: S49–55
   PubMed Web of Science ®Google Scholar
• Tager I B, Segal M R, Speizer F E, Weiss S T. The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms. Amer Rev Respir Dis 1988; 138: 837–849
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645–1648
   PubMed Web of Science ®Google Scholar
• Mannino D M, Davis K J. Lung function decline and outcomes in an elderly population. Thorax 2006; 61: 472–477
   PubMed Web of Science ®Google Scholar
• Mannino D M, Reichert M M, Davis K J. Lung function decline and outcomes in an adult population. Amer J Respir Crit Care Med 2006; 173: 985–990
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Connett J E, Kiley J P, Altose M D, Bailey W C, Buist A S, Conway W A, Jr, Enright P L, Kanner R E, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of fev1. The lung health study. JAMA 1994; 272: 1497–1505
   PubMed Web of Science ®Google Scholar
• Tashkin D P, Altose M D, Connett J E, Kanner R E, Lee W W, Wise R A. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The lung health study research group. Amer J Respir Crit Care Med 1996; 153: 1802–1811
   PubMed Web of Science ®Google Scholar
• Anthonisen N R. Lessons from the lung health study. Proc Amer Thor Soc 2004; 1: 143–145
   PubMedGoogle Scholar
• Kanner R E, Anthonisen N R, Connett J E. Lower respiratory illnesses promote fev(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: Results from the lung health study. Amer J Respir Critical Care Med 2001; 164: 358–364
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R, Tinkeer C, Speizer F E. The natural history of chornic bronchitis and emphsema. 1976
   Google Scholar
• Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with fev1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Amer J Respir Crit Care Med 1996; 153: 1530–1535
   PubMed Web of Science ®Google Scholar
• Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. New Engl J Med 1998; 339: 1194–1200
   PubMed Web of Science ®Google Scholar
• Almind M, Viskum K, Evald T, Dirksen A, Kok-Jensen A. A seven-year follow-up study of 343 adults with bronchial asthma. Dan Med Bull 1992; 39: 561–565
   PubMed Web of Science ®Google Scholar
• Sherrill D, Guerra S, Bobadilla A, Barbee R. The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics. Eur Respir J 2003; 21: 95–100
   PubMed Web of Science ®Google Scholar
• Sandford A J, Chagani T, Weir T D, Connett J E, Anthonisen N R, Pare P D. Susceptibility genes for rapid decline of lung function in the lung health study. Amer J Respir Crit Care Med 2001; 163: 469–473
   PubMed Web of Science ®Google Scholar
• Joos L, Weir T D, Connett J E, Anthonisen N R, Woods R, Pare P D, Sandford A J. Polymorphisms in the beta2 adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness, and rate of decline in lung function in smokers. Thorax 2003; 58: 703–707
   PubMed Web of Science ®Google Scholar
• Ogawa E, Ruan J, Connett J E, Anthonisen N R, Pare P D, Sandford A J. Transforming growth factor-beta1 polymorphisms, airway responsiveness and lung function decline in smokers. Respir Med 2006
   Web of Science ®Google Scholar
• Boyd G, Morice A H, Pounsford J C, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (copd). Eur Respir J 1997; 10: 815–821
   PubMed Web of Science ®Google Scholar
• Oberbeck R, Dahlweid M, Koch R, van Griensven M, Emmendorfer A, Tscherne H, Pape H C. Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Critical Care Med 2001; 29: 380–384
   PubMed Web of Science ®Google Scholar
• Wadbo M, Lofdahl C G, Larsson K, Skoogh B E, Tornling G, Arwestrom E, Bengtsson T, Strom K. Effects of formoterol and ipratropium bromide in copd: A 3-month placebo-controlled study. Eur Respir J 2002; 20: 1138–1146
   PubMed Web of Science ®Google Scholar
• Dahl R, Greefhorst L A, Nowak D, Nonikov V, Byrne A M, Thomson M H, Till D, Della Cioppa G. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 2001; 164: 778–784
   PubMed Web of Science ®Google Scholar
• Jones P W, Bosh T K. Quality of life changes in copd patients treated with salmeterol. Amer J Respir Crit Care Med 1997; 155: 1283–1289
   PubMed Web of Science ®Google Scholar
• Calverley P M, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912–919
   PubMed Web of Science ®Google Scholar
• Liesker J J, Van De Velde V, Meysman M, Vincken W, Wollmer P, Hansson L, Kerstjens H A, Qvint U, Pauwels R A. Effects of formoterol (oxis turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir Med 2002; 96: 559–566
   PubMed Web of Science ®Google Scholar
• Soriano J B, Vestbo J, Pride N B, Kiri V, Maden C, Maier W C. Survival in copd patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20: 819–825
   PubMed Web of Science ®Google Scholar
• van Schayck C P, Dompeling E, van Herwaarden C L, Folgering H, Akkermans R P, van den Broek P J, van Weel C. Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: Four-year follow-up randomized controlled study. Br J Gen Pract 1995; 45: 239–244
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Lindgren P G, Tashkin D P, Kanner R E, Scanlon P D, Connett J E. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 2005; 26: 45–51
   PubMed Web of Science ®Google Scholar
• Calverley P M, Burge P S, Spencer S, Anderson J A, Jones P W. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659–664
   PubMed Web of Science ®Google Scholar
• Celedon J C, Speizer F E, Drazen J M, Weiss S T, Campbell E J, Carey V J, Reilly J J, Ginns L, Silverman E K. Bronchodilator responsiveness and serum total ige levels in families of probands with severe early-onset COPD. Eur Respir J 1999; 14: 1009–1014
   PubMed Web of Science ®Google Scholar
• Palmer L J, Celedon J C, Chapman H A, Speizer F E, Weiss S T, Silverman E K. Genome-wide linkage analysis of bronchodilator responsiveness and post-bronchodilator spirometric phenotypes in chronic obstructive pulmonary disease. Human Mol Gen 2003; 12: 1199–1210
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord J A, Greefhorst A P, Bantje T A, Kesten S, Korducki L, Cornelissen P J. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209–216
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler D A, Jones P W, Wanner A, San P G, Zu Wallack R L, Menjoge S S, Serby C W, Witek T, Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–224
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in copd. Eur Respir J 2004; 23: 832–840
   PubMed Web of Science ®Google Scholar
• Casaburi R, Kukafka D, Cooper C B, Witek T J. Jr., Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with copd. Chest 2005; 127: 809–817
   PubMed Web of Science ®Google Scholar
• Tashkin D P, Altose M D, Bleecker E R, Connett J E, Kanner R E, Lee W W, Wise R. The lung health study: Airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The lung health study research group. Amer Rev Respir Dis 1992; 145: 301–310
   PubMed Web of Science ®Google Scholar
• Wise R A, Kanner R E, Lindgren P, Connett J E, Altose M D, Enright P L, Tashkin D P. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: The lung health study. Chest 2003; 124: 449–458
   PubMed Web of Science ®Google Scholar
• Brutsche M H, Downs S H, Schindler C, Gerbase M W, Schwartz J, Frey M, Russi E W, Ackermann-Liebrich U, Leuenberger P. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: Sapaldia cohort study. Thorax 2006; 61: 671–677
   PubMed Web of Science ®Google Scholar
• Postma D S, Kerstjens H A. Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 1998; 158: S187–192
   PubMedGoogle Scholar
• Meyers D A, Larj M J, Lange L. Genetics of asthma and COPD. Similar results for different phenotypes. Chest 2004; 126: 105S–110S, discussion 159S–161S
   PubMedGoogle Scholar
• Robinson R W, White D P, Zwillich C W. Relationship of respiratory drives to dyspnea and exercise performance in chronic obstructive pulmonary disease. Amer Rev Respir Dis 1987; 136: 1084–1090
   PubMed Web of Science ®Google Scholar
• Cloosterman S G, Hofland I D, van Schayck C P, Folgering H T. Exertional dyspnoea in patients with airway obstruction, with and without CO2 retention. Thorax 1998; 53: 768–774
   PubMed Web of Science ®Google Scholar
• Gorini M, Misuri G, Corrado A, Duranti R, Iandelli I, De Paola E, Scano G. Breathing pattern and carbon dioxide retention in severe chronic obstructive pulmonary disease. Thorax 1996; 51: 677–683
   PubMed Web of Science ®Google Scholar
• Johnson M A, Woodcock A A, Rehahn M, Geddes D M. Are “Pink puffers” more breathless than “Blue bloaters”?. Br Med J (Clin Res Ed) 1983; 286: 179–182
   PubMed Web of Science ®Google Scholar
• Marin J M, Montes de Oca M, Rassulo J, Celli B R. Ventilatory drive at rest and perception of exertional dyspnea in severe copd. Chest 1999; 115: 1293–1300
   PubMed Web of Science ®Google Scholar
• Ferrari K, Goti P, Duranti R, Iandelli I, Misuri G, Mancini M, Rosi E, Scano G. Breathlessness and control of breathing in patients with copd Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio,. Universita di Napoli, Secondo ateneo 1997; 52: 18–23
   Google Scholar
• Nizet T A, van den Elshout F J, Heijdra Y F, van de Ven M J, Mulder P G, Folgering H T. Survival of chronic hypercapnic COPD patients is predicted by smoking habits, comorbidity, and hypoxemia. Chest 2005; 127: 1904–1910
   PubMed Web of Science ®Google Scholar
• Jones P W. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56: 880–887
   PubMed Web of Science ®Google Scholar
• Celli B R, MacNee W. Standards for the diagnosis and treatment of patients with copd: A summary of the ats/ers position paper. Eur Respir J 2004; 23: 932–946
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Exercise capacity deterioration in patients with COPD: Longitudinal evaluation over 5 years. Chest 2005; 128: 62–69
   PubMed Web of Science ®Google Scholar
• Pinto-Plata V M, Cote C, Cabral H, Taylor J, Celli B R. The 6-min walk distance: Change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23: 28–33
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: Role of exercise capacity and health status. Amer J Respir Crit Care Med 2003; 167: 544–549
   PubMed Web of Science ®Google Scholar
• Arnardottir R H, Emtner M, Hedenstrom H, Larsson K, Boman G. Peak exercise capacity estimated from incremental shuttle walking test in patients with COPD: A methodological study. Respir Res 2006; 7: 127
   PubMed Web of Science ®Google Scholar
• European Respiratory Society. Clinical exercise testing with reference to lung diseases: Indications, standardization and interpretation strategies. Ers task force on standardization of clinical exercise testing. Eur Respir J 1997; 10: 2662–2689
   PubMed Web of Science ®Google Scholar
• ATS Statement. Guidelines for the six-minute walk test. Amer J Respir Crit Care Med 2002; 166: 111–117
   PubMed Web of Science ®Google Scholar
• McGavin C R, Gupta S P, McHardy G J. Twelve-minute walking test for assessing disability in chronic bronchitis. Br Med J 1976; 1: 822–823
   PubMed Web of Science ®Google Scholar
• Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood D E. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059–2073
   PubMed Web of Science ®Google Scholar
• Bernstein M L, Despars J A, Singh N P, Avalos K, Stansbury D W, Light R W. Reanalysis of the 12-minute walk in patients with chronic obstructive pulmonary disease. Chest 1994; 105: 163–167
   PubMed Web of Science ®Google Scholar
• Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. AmerJ Respir Crit Care Med 1998; 158: 1185–1189
   PubMed Web of Science ®Google Scholar
• Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 1999; 159: 158–164
   PubMed Web of Science ®Google Scholar
• Singh S J, Morgan M D, Scott S, Walters D, Hardman A E. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 1019–1024
   PubMed Web of Science ®Google Scholar
• Ferguson G T. Why does the lung hyperinflate?. Proc Amer Thor Soc 2006; 3: 176–179
   PubMedGoogle Scholar
• Leith D E, Brown R. Human lung volumes and the mechanisms that set them. Eur Respir J 1999; 13: 468–472
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Bertley J C, Chau L K, Webb K A. Qualitative aspects of exertional breathlessness in chronic airflow limitation: Pathophysiologic mechanisms. Amer J Respir Crit Care Med 1997; 155: 109–115
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Revill S M, Webb K A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 2001; 164: 770–777
   PubMed Web of Science ®Google Scholar
• O'Donnell D E. Ventilatory limitations in chronic obstructive pulmonary disease. Med Sci Sports Exer 2001; 33: S647–655
   PubMed Web of Science ®Google Scholar
• Cooper C B. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Amer J Med 2006; 119: 21–31
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Voduc N, Fitzpatrick M, Webb K A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 86–94
   PubMed Web of Science ®Google Scholar
• Cotton D J, Soparkar G R, Grahan B L. Diffusing capacity in the clinical assessment of chronic airflow limitation. Med Clinics North Amer 1996; 80: 549–564
   PubMed Web of Science ®Google Scholar
• Makita H, Nasuhara Y, Betsuyaku T, Onodera Y, Hizawa N, Nishimura M. Characterization of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007, in press
   PubMed Web of Science ®Google Scholar
• Mohsenifar Z, Lee S M, Diaz P, Criner G, Sciurba F, Ginsburg M, Wise R A. Single-breath diffusing capacity of the lung for carbon monoxide: A predictor of pao2, maximum work rate, and walking distance in patients with emphysema. Chest 2003; 123: 1394–1400
   PubMed Web of Science ®Google Scholar
• Rubin L J. Diagnosis and management of pulmonary arterial hypertension: Accp evidence-based clinical practice guidelines. Chest 2004; 126: 4S–6S
   Web of Science ®Google Scholar
• Rubin L J, Badesch D B. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005; 143: 282–292
   PubMed Web of Science ®Google Scholar
• Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36: 752–758
   PubMed Web of Science ®Google Scholar
• Wright J L, Levy R D, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: Current theories of pathogenesis and their implications for treatment. Thorax 2005; 60: 605–609
   PubMed Web of Science ®Google Scholar
• Cooper R, Ghali J, Simmons B E, Castaner A. Elevated pulmonary artery pressure. An independent predictor of mortality. Chest 1991; 99: 112–120
   PubMed Web of Science ®Google Scholar
• Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, Ehrhart M, Oswald-Mammosser M. “Natural history” Of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Amer J Respir Crit Care Med 2001; 164: 219–224
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Chaouat A, Morrell N, Fadel E, Fuhrman C, Bugnet A S, Dartevelle P, Housset B, Hamon M, Weitzenblum E, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108: 1839–1844
   PubMed Web of Science ®Google Scholar
• Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Amer Thorac Soc 2005; 2: 20–22
   PubMedGoogle Scholar
• Scharf S M, Iqbal M, Keller C, Criner G, Lee S, Fessler H E. Hemodynamic characterization of patients with severe emphysema. Amer J Respir Critical Care Med 2002; 166: 314–322
   PubMed Web of Science ®Google Scholar
• Rubin L J. Primary pulmonary hypertension. New Engl J Med 1997; 336: 111–117
   PubMed Web of Science ®Google Scholar
• Naeije R, Barbera J A. Pulmonary hypertension associated with COPD. Crit Care (London, England) 2001; 5: 286–289
   PubMed Web of Science ®Google Scholar
• Lejeune P, Mols P, Naeije R, Hallemans R, Melot C. Acute hemodynamic effects of controlled oxygen therapy in decompensated chronic obstructive pulmonary disease. Crit Care Med 1984; 12: 1032–1035
   PubMed Web of Science ®Google Scholar
• Timms R M, Khaja F U, Williams G W. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 1985; 102: 29–36
   PubMed Web of Science ®Google Scholar
• Peinado V I, Barbera J A, Abate P, Ramirez J, Roca J, Santos S, Rodriguez-Roisin R. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 1999; 159: 1605–1611
   PubMed Web of Science ®Google Scholar
• Wilkinson M, Langhorne C A, Heath D, Barer G R, Howard P. A pathophysiological study of 10 cases of hypoxic cor pulmonale. Quart J Med 1988; 66: 65–85
   PubMedGoogle Scholar
• Wright J L, Tai H, Churg A. Cigarette smoke induces persisting increases of vasoactive mediators in pulmonary arteries. Amer J Respir Cell Mol Biol 2004; 31: 501–509
   PubMed Web of Science ®Google Scholar
• Nakano Y, Muro S, Sakai H, Hirai T, Chin K, Tsukino M, Nishimura K, Itoh H, Pare P D, Hogg J C, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Amer J Respir Crit Care Med 2000; 162: 1102–1108
   PubMed Web of Science ®Google Scholar
• Coxson H O, Rogers R M, Whittall K P, D'Yachkova Y, Pare P D, Sciurba F C, Hogg J C. A quantification of the lung surface area in emphysema using computed tomography. Amer J Respir Crit Care Med 1999; 159: 851–856
   PubMed Web of Science ®Google Scholar
• Nishimura K, Murata K, Yamagishi M, Itoh H, Ikeda A, Tsukino M, Koyama H, Sakai N, Mishima M, Izumi T. Comparison of different computed tomography scanning methods for quantifying emphysema. J Thorac Imag 1998; 13: 193–198
   PubMed Web of Science ®Google Scholar
• Sakai N, Mishima M, Nishimura K, Itoh H, Kuno K. An automated method to assess the distribution of low attenuation areas on chest ct scans in chronic pulmonary emphysema patients. Chest 1994; 106: 1319–1325
   PubMed Web of Science ®Google Scholar
• Gevenois P A, de Maertelaer V, De Vuyst P, Zanen J, Yernault J C. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Amer J Respir Crit Care Med 1995; 152: 653–657
   PubMed Web of Science ®Google Scholar
• Gevenois P A, De Vuyst P, de Maertelaer V, Zanen J, Jacobovitz D, Cosio M G, Yernault J C. Comparison of computed density and microscopic morphometry in pulmonary emphysema. Amer J Respir Crit Care Med 1996; 154: 187–192
   PubMed Web of Science ®Google Scholar
• Gevenois P A, De Vuyst P, Sy M, Scillia P, Chaminade L, de Maertelaer V, Zanen J, Yernault J C. Pulmonary emphysema: Quantitative CT during expiration. Radiology 1996; 199: 825–829
   PubMed Web of Science ®Google Scholar
• Gurney J W, Jones K K, Robbins R A, Gossman G L, Nelson K J, Daughton D, Spurzem J R, Rennard S I. Regional distribution of emphysema: Correlation of high-resolution CT with pulmonary function tests in unselected smokers. Radiology 1992; 183: 457–463
   PubMed Web of Science ®Google Scholar
• Kinsella M, Muller N L, Abboud R T, Morrison N J. DyBuncio A. Quantitation of emphysema by computed tomography using a “Density mask” Program and correlation with pulmonary function tests. Chest 1990; 97: 315–321
   PubMed Web of Science ®Google Scholar
• Kuwano K, Matsuba K, Ikeda T, Murakami J, Araki A, Nishitani H, Ishida T, Yasumoto K, Shigematsu N. The diagnosis of mild emphysema. Correlation of computed tomography and pathology scores. Amer Rev Respir Dis 1990; 141: 169–178
   PubMed Web of Science ®Google Scholar
• Lamers R J, Thelissen G R, Kessels A G, Wouters E F, van Engelshoven J M. Chronic obstructive pulmonary disease: Evaluation with spirometrically controlled CT lung densitometry. Radiology 1994; 193: 109–113
   PubMed Web of Science ®Google Scholar
• Mishima M, Hirai T, Itoh H, Nakano Y, Sakai H, Muro S, Nishimura K, Oku Y, Chin K, Ohi M, et al. Complexity of terminal airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 1999; 96: 8829–8834
   PubMed Web of Science ®Google Scholar
• Mishima M, Hirai T, Jin Z, Oku Y, Sakai N, Nakano Y, Sakai H, Chin K, Ohi M, Kawakami K, et al. Standardization of low attenuation area versus total lung area in chest X-ray CT as an indicator of chronic pulmonary emphysema. Front Med Biol Eng 1997; 8: 79–86
   PubMedGoogle Scholar
• Mishima M, Itoh H, Sakai H, Nakano Y, Muro S, Hirai T, Takubo Y, Chin K, Ohi M, Nishimura K, et al. Optimized scanning conditions of high resolution CT in the follow-up of pulmonary emphysema. J Comput Assist Tomogr 1999; 23: 380–384
   PubMed Web of Science ®Google Scholar
• Mishima M, Oku Y, Kawakami K, Sakai N, Fukui M, Hirai T, Chin K, Ohi M, Nishimura K, Itoh H, et al. Quantitative assessment of the spatial distribution of low attenuation areas on X-ray CT using texture analysis in patients with chronic pulmonary emphysema. Front Med Biol Eng 1997; 8: 19–34
   PubMedGoogle Scholar
• Muller N L, Staples C A, Miller R R, Abboud R T. “Density mask”. An objective method to quantitate emphysema using computed tomography. Chest 1988; 94: 782–787
   PubMed Web of Science ®Google Scholar
• Nakano Y, Sakai H, Muro S, Hirai T, Oku Y, Nishimura K, Mishima M. Comparison of low attenuation areas on computed tomographic scans between inner and outer segments of the lung in patients with chronic obstructive pulmonary disease: Incidence and contribution to lung function. Thorax 1999; 54: 384–389
   PubMed Web of Science ®Google Scholar
• Nakano Y, Wong J C, de Jong P A, Buzatu L, Nagao T, Coxson H O, Elliott W M, Hogg J C, Pare P D. The prediction of small airway dimensions using computed tomography. Amer J Respir Crit Care Med 2005; 171: 142–146
   PubMed Web of Science ®Google Scholar
• Vikgren J, Boijsen M, Andelid K, Ekberg-Jansson A, Larsson S, Bake B, Tylen U. High-resolution computed tomography in healthy smokers and never-smokers: A 6-year follow-up study of men born in 1933. Acta Radiol 2004; 45: 44–52
   PubMed Web of Science ®Google Scholar
• Hruban R H, Meziane M A, Zerhouni E A, Khouri N F, Fishman E K, Wheeler P S, Dumler J S, Hutchins G M. High resolution computed tomography of inflation-fixed lungs. Pathologic-radiologic correlation of centrilobular emphysema. Amer Rev Respir Dis 1987; 136: 935–940
   PubMed Web of Science ®Google Scholar
• Foster W L, Jr, Pratt P C, Roggli V L, Godwin J D, Halvorsen R A, Jr, Putman C E. Centrilobular emphysema: Ct-pathologic correlation. Radiology 1986; 159: 27–32
   PubMed Web of Science ®Google Scholar
• Foster W L, Jr, Gimenez E I, Roubidoux M A, Sherrier R H, Shannon R H, Roggli V L, Pratt P C. The emphysemas: Radiologic-pathologic correlations. Radiographics 1993; 13: 311–328
   PubMed Web of Science ®Google Scholar
• Copley S J, Wells A U, Muller N L, Rubens M B, Hollings N P, Cleverley J R, Milne D G, Hansell D M. Thin-section CT in obstructive pulmonary disease: Discriminatory value. Radiology 2002; 223: 812–819
   PubMed Web of Science ®Google Scholar
• Satoh K, Kobayashi T, Misao T, Hitani Y, Yamamoto Y, Nishiyama Y, Ohkawa M. Ct assessment of subtypes of pulmonary emphysema in smokers. Chest 2001; 120: 725–729
   PubMed Web of Science ®Google Scholar
• Stern E J, Webb W R, Weinacker A, Muller N L. Idiopathic giant bullous emphysema (vanishing lung syndrome): Imaging findings in nine patients. AJR Am J Roentgenol 1994; 162: 279–282
   PubMed Web of Science ®Google Scholar
• Kim W D, Eidelman D H, Izquierdo J L, Ghezzo H, Saetta M P, Cosio M G. Centrilobular and panlobular emphysema in smokers. Two distinct morphologic and functional entities. Am Rev Respir Dis 1991; 144: 1385–1390
   PubMed Web of Science ®Google Scholar
• Saetta M, Kim W D, Izquierdo J L, Ghezzo H, Cosio M G. Extent of centrilobular and panacinar emphysema in smokers' lungs: Pathological and mechanical implications. Eur Respir J 1994; 7: 664–671
   PubMed Web of Science ®Google Scholar
• Hogg J C, Senior R M. Chronic obstructive pulmonary disease—part 2: Pathology and biochemistry of emphysema. Thorax 2002; 57: 830–834
   PubMed Web of Science ®Google Scholar
• Sugi K, Kaneda Y, Murakami T, Esato K. The outcome of volume reduction surgery according to the underlying type of emphysema. Surg Today 2001; 31: 580–585
   PubMed Web of Science ®Google Scholar
• Goddard P R, Nicholson E M, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. Clin Radiol 1982; 33: 379–387
   PubMed Web of Science ®Google Scholar
• Bergin C J, Muller N L, Miller R R. Ct in the qualitative assessment of emphysema. J Thorac Imaging 1986; 1: 94–103
   PubMedGoogle Scholar
• Coddington R, Mera S L, Goddard P R, Bradfield J W. Pathological evaluation of computed tomography images of lungs. J Clin Pathol 1982; 35: 536–540
   PubMed Web of Science ®Google Scholar
• Thurlbeck W M, Muller N L. Emphysema: Definition, imaging, and quantification. AJR Am J Roentgenol 1994; 163: 1017–1025
   PubMed Web of Science ®Google Scholar
• Klein J S, Gamsu G, Webb W R, Golden J A, Muller N L. High-resolution ct diagnosis of emphysema in symptomatic patients with normal chest radiographs and isolated low diffusing capacity. Radiology 1992; 182: 817–821
   PubMed Web of Science ®Google Scholar
• Spaggiari E, Zompatori M, Verduri A, Chetta A, Bna C, Ormitti F, Sverzellati N, Rabaiotti E. Early smoking-induced lung lesions in asymptomatic subjects. Correlations between high resolution dynamic ct and pulmonary function testing. Radiol Med (Torino) 2005; 109: 27–39
   PubMed Web of Science ®Google Scholar
• Baldi S, Miniati M, Bellina C R, Battolla L, Catapano G, Begliomini E, Giustini D, Giuntini C. Relationship between extent of pulmonary emphysema by high-resolution computed tomography and lung elastic recoil in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 585–589
   PubMed Web of Science ®Google Scholar
• Gelb A F, Hogg J C, Muller N L, Schein M J, Kuei J, Tashkin D P, Epstein J D, Kollin J, Green R H, Zamel N, et al. Contribution of emphysema and small airways in COPD. Chest 1996; 109: 353–359
   PubMed Web of Science ®Google Scholar
• Sanders C, Nath P H, Bailey W C. Detection of emphysema with computed tomography. Correlation with pulmonary function tests and chest radiography. Invest Radiol 1988; 23: 262–266
   PubMed Web of Science ®Google Scholar
• Gelb A F, Zamel N, Hogg J C, Muller N L, Schein M J. Pseudophysiologic emphysema resulting from severe small-airways disease. Am J Respir Crit Care Med 1998; 158: 815–819
   PubMed Web of Science ®Google Scholar
• Zeidler M R, Kleerup E C, Goldin J G, Kim H J, Truong D A, Simmons M D, Sayre J W, Liu W, Elashoff R, Tashkin D P. Montelukast improves regional air-trapping due to small airways obstruction in asthma. Eur Respir J 2006; 27: 307–315
   PubMed Web of Science ®Google Scholar
• Jain N, Covar R A, Gleason M C, Newell J D, Jr, Gelfand E W, Spahn J D. Quantitative computed tomography detects peripheral airway disease in asthmatic children. Pediatr Pulmonol 2005; 40: 211–218
   PubMed Web of Science ®Google Scholar
• Grenier P A, Beigelman-Aubry C, Fetita C, Preteux F, Brauner M W, Lenoir S. New frontiers in ct imaging of airway disease. Eur Radiol 2002; 12: 1022–1044
   PubMed Web of Science ®Google Scholar
• Goldin J G. Quantitative ct of the lung. Radiol Clin North Am 2002; 40: 145–162
   PubMed Web of Science ®Google Scholar
• Newman K B, Lynch D A, Newman L S, Ellegood D, Newell J D. Jr. Quantitative computed tomography detects air trapping due to asthma. Chest 1994; 106: 105–109
   PubMed Web of Science ®Google Scholar
• Remy-Jardin M, Edme J L, Boulenguez C, Remy J, Mastora I, Sobaszek A. Longitudinal follow-up study of smoker's lung with thin-section CT in correlation with pulmonary function tests. Radiology 2002; 222: 261–270
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Kurihara Y, Yagihashi K, Nakajima Y. Morphological progression of emphysema on thin-section ct: Analysis of longitudinal change in the number and size of low-attenuation clusters. J Comput Assist Tomogr 2006; 30: 669–674
   PubMed Web of Science ®Google Scholar
• Kitaguchi Y, Fujimoto K, Kubo K, Honda T. Characteristics of COPD phenotypes classified according to the findings of hrct. Respir Med 2006; 100: 1742–1752
   PubMed Web of Science ®Google Scholar
• Eriksson S. Studies in alpha 1-antitrypsin deficiency. Acta Med Scand Suppl 1965; 432: 1–85
   PubMedGoogle Scholar
• Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin pi-types in 965 COPD patients. Chest 1986; 89: 370–373
   PubMed Web of Science ®Google Scholar
• Eriksson S. Discovery of alpha 1-antitrypsin deficiency. Lung 1990; 523–529, 168 Suppl
   PubMed Web of Science ®Google Scholar
• Sakao S, Tatsumi K, Igari H, Watanabe R, Shino Y, Shirasawa H, Kuriyama T. Association of tumor necrosis factor-alpha gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD. Chest 2002; 122: 416–420
   PubMed Web of Science ®Google Scholar
• Ito I, Nagai S, Handa T, Muro S, Hirai T, Tsukino M, Mishima M. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005; 172: 1378–1382
   PubMed Web of Science ®Google Scholar
• Minematsu N, Nakamura H, Iwata M, Tateno H, Nakajima T, Takahashi S, Fujishima S, Yamaguchi K. Association of cyp2a6 deletion polymorphism with smoking habit and development of pulmonary emphysema. Thorax 2003; 58: 623–628
   PubMed Web of Science ®Google Scholar
• Silverman E K. Progress in chronic obstructive pulmonary disease genetics. Proc Am Thorac Soc 2006; 3: 405–408
   PubMedGoogle Scholar
• Sampsonas F, Karkoulias K, Kaparianos A, Spiropoulos K. Genetics of chronic obstructive pulmonary disease, beyond a1-antitrypsin deficiency. Curr Med Chem 2006; 13: 2857–2873
   PubMed Web of Science ®Google Scholar
• Wood A M, Stockley R A. The genetics of chronic obstructive pulmonary disease. Respir Res 2006; 7: 130
   PubMed Web of Science ®Google Scholar
• Cookson W O. State of the art. Genetics and genomics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 473–475
   PubMedGoogle Scholar
• Joos L. Copd and genetics–what's new?. Swiss Med Wkly 2004; 134: 437–439
   PubMed Web of Science ®Google Scholar
• Molfino N A. Genetics of COPD. Chest 2004; 125: 1929–1940
   PubMed Web of Science ®Google Scholar
• Hoidal J R. Genetics of COPD: Present and future. Eur Respir J 2001; 18: 741–743
   PubMed Web of Science ®Google Scholar
• Hogg J C, Chu F, Utokaparch S, Woods R, Elliott W M, Buzatu L, Cherniack R M, Rogers R M, Sciurba F C, Coxson H O, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645–2653
   PubMed Web of Science ®Google Scholar
• Pedersen S K, Sloane A J, Prasad S S, Sebastian L T, Lindner R A, Hsu M, Robinson M, Bye P T, Weinberger R P, Harry J L. An immunoproteomic approach for identification of clinical biomarkers for monitoring disease: Application to cystic fibrosis. Mol Cell Proteomics 2005; 4: 1052–1060
   PubMed Web of Science ®Google Scholar
• Orlandi I, Moroni C, Camiciottoli G, Bartolucci M, Pistolesi M, Villari N, Mascalchi M. Chronic obstructive pulmonary disease: Thin-section ct measurement of airway wall thickness and lung attenuation. Radiology 2005; 234: 604–610
   PubMed Web of Science ®Google Scholar
• Aziz Z A, Wells A U, Desai S R, Ellis S M, Walker A E, MacDonald S, Hansell D M. Functional impairment in emphysema: Contribution of airway abnormalities and distribution of parenchymal disease. AJR Am J Roentgenol 2005; 185: 1509–1515
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Nasuhara Y, Onodera Y, Makita H, Nagai K, Fuke S, Ito Y, Betsuyaku T, Nishimura M. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 1309–1315
   PubMed Web of Science ®Google Scholar
• Tschirren J, Hoffman E A. McLennan G Sonka M. Intrathoracic airway trees: Segmentation and airway morphology analysis from low-dose ct scans. IEEE Trans Med Imaging 2005; 24: 1529–1539
   PubMed Web of Science ®Google Scholar
• Heyneman L E, Ward S, Lynch D A, Remy-Jardin M, Johkoh T, Muller N L. Respiratory bronchiolitis, respiratory bronchiolitis-associated interstitial lung disease, and desquamative interstitial pneumonia: Different entities or part of the spectrum of the same disease process?. AJR Am J Roentgenol 1999; 173: 1617–1622
   PubMed Web of Science ®Google Scholar
• Moon J, du Bois R M, Colby T V, Hansell D M, Nicholson A G. Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease. Thorax 1999; 54: 1009–1014
   PubMed Web of Science ®Google Scholar
• Park J S, Brown K K, Tuder R M, Hale V A, King T E, Jr, Lynch D A. Respiratory bronchiolitis-associated interstitial lung disease: Radiologic features with clinical and pathologic correlation. J Comput Assist Tomogr 2002; 26: 13–20
   PubMed Web of Science ®Google Scholar
• Afessa B, Morales I J, Scanlon P D, Peters S G. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. Crit Care Med 2002; 30: 1610–1615
   PubMed Web of Science ®Google Scholar
• Okada Y, Nagase H, Harris E D, Jr. Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. J Rheumatol 1987; 41–42, 14 Spec No
   PubMed Web of Science ®Google Scholar
• Joos L, He J Q, Shepherdson M B, Connett J E, Anthonisen N R, Pare P D, Sandford A J. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Human Mol Genet 2002; 11: 569–576
   PubMed Web of Science ®Google Scholar
• Maines M D. The heme oxygenase system: A regulator of second messenger gases. Ann Rev Pharmacol Toxicol 1997; 37: 517–554
   PubMed Web of Science ®Google Scholar
• He J Q, Ruan J, Connett J E, Anthonisen N R, Pare P D, Sandford A J. Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. Amer J Respir Crit Care Med 2002; 166: 323–328
   PubMed Web of Science ®Google Scholar
• Horne S L, Cockcroft D W, Dosman J A. Possible protective effect against chronic obstructive airways disease by the gc2 allele. Human Hered 1990; 40: 173–176
   PubMed Web of Science ®Google Scholar
• Kew R R, Fisher J A, Webster R O. Co-chemotactic effect of gc-globulin (vitamin d binding protein) for c5a. Transient conversion into an active co-chemotaxin by neutrophils. J Immunol 1995; 155: 5369–5374
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Homma S. Vitamin d3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 1991; 88: 8539–8543
   PubMed Web of Science ®Google Scholar
• Bouma G, Crusius J B, Oudkerk Pool M, Kolkman J J, von Blomberg B M, Kostense P J, Giphart M J, Schreuder G M, Meuwissen S G, Pena A S. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the tnf genes and hla-dr alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996; 43: 456–463
   PubMed Web of Science ®Google Scholar
• Turki J, Pak J, Green S A, Martin R J, Liggett S B. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that gly16 correlates with the nocturnal phenotype. J Clin Invest 1995; 95: 1635–1641
   PubMed Web of Science ®Google Scholar
• Weir T D, Mallek N, Sandford A J, Bai T R, Awadh N, Fitzgerald J M, Cockcroft D, James A, Liggett S B, Pare P D. β2-adrenergic receptor haplotypes in mild, moderate and fatal/ near fatal asthma. Amer J Respir Crit Care Med 1998; 158: 787–791
   PubMed Web of Science ®Google Scholar
• Hall I P, Wheatley A, Wilding P, Liggett S B. Association of glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995; 345: 1213–1214
   PubMed Web of Science ®Google Scholar
• Ramsay C E, Hayden C M, Tiller K J, Burton P R, Goldblatt J, Lesouef P N. Polymorphisms in the beta2-adrenoreceptor gene are associated with decreased airway responsiveness. Clin Exp Allergy 1999; 29: 1195–1203
   PubMed Web of Science ®Google Scholar
• D'Amato M, Vitiani L R, Petrelli G, Ferrigno L, di Pietro A, Trezza R, Matricardi P M. Association of persistent bronchial hyperresponsiveness with beta2-adrenoceptor (adrb2) haplotypes. A population study. Amer J Respir Crit Care Med 1998; 158: 1968–1973
   PubMed Web of Science ®Google Scholar
• Lima J J, Thomason D B, Mohamed M H, Eberle L V, Self T H, Johnson J A. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Therap 1999; 65: 519–525
   PubMed Web of Science ®Google Scholar
• Martinez F D, Graves P E, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 3184–3188
   PubMed Web of Science ®Google Scholar
• Ulbrecht M, Hergeth M T, Wjst M, Heinrich J, Bickeboller H, Wichmann H E, Weiss E H. Association of beta(2)-adrenoreceptor variants with bronchial hyperresponsiveness. Amer J Respir Crit Care Med 2000; 161: 469–474
   PubMed Web of Science ®Google Scholar
• Summerhill E, Leavitt S A, Gidley H, Parry R, Solway J, Ober C. β(2)-adrenergic receptor arg16/arg16 genotype is associated with reduced lung function, but not with asthma, in the hutterites. Amer J Respir Crit Care Med 2000; 162: 599–602
   PubMed Web of Science ®Google Scholar
• Mannervik B. The isoenzymes of glutathione transferase. Adv Enzymol Related Areas Mol Biol 1985; 57: 357–417
   PubMedGoogle Scholar
• Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, Okada Y, Yamasawa F, Nakahara K, Umeda A. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Amer J Respir Crit Care Med 2001; 163: 1476–1483
   PubMed Web of Science ®Google Scholar
• de Boer W I, van Schadewijk A, Sont J K, Sharma H S, Stolk J, Hiemstra P S, van Krieken J H. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Amer J Respir Crit Care Med 1998; 158: 1951–1957
   PubMed Web of Science ®Google Scholar
• Chung K F. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001; 34: 50s–59s
   Google Scholar